Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Status:
NOT_YET_RECRUITING
Trial end date:
2033-09-30
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.